BioMarin appoints Ian Clark as Chair of the Board

BioMarin (BMRN) Pharmaceutical said that the Board of Directors has appointed Ian T. Clark as Chair of the Board, subject to his election at the company’s Annual Meeting of Stockholders on June 2. Clark will succeed Richard A. Meier, who is retiring after two decades on the Board, and the appointment will become effective immediately following the Annual Meeting. Clark joined BioMarin’s Board in 2025 and brings extensive board, governance and executive leadership experience across the global biopharmaceutical industry. He has served on the boards of a number of public biopharmaceutical companies, including roles as lead independent director and chair. He was CEO of Genentech and a member of Genentech’s Board of Directors from 2010 to 2016. Meier joined BioMarin’s Board in 2006, playing a key role in the company’s evolution. He was Lead Independent Director before being elected Chair in 2023. During this period, profitability improved meaningfully, with significant expansion in non-GAAP operating margin, earnings-per-share growth and substantial cash flow generation.